Evolving concepts of diagnosis and classification

Scleroderma: From Pathogenesis to Comprehensive Management

Volumn , Issue , 2012, Pages 53-69

  Chung, Lorinda ^a   Fransen, Jaap ^b   Van den Hoogen, Frank H J ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SINT MAARTENSKLINIEK   (Netherlands)

Author keywords

Classification; Clinical subsets of systemic sclerosis; Diagnosis; Evolving concepts; Limitations; Original leroy classification; Scleroderma sine sclerosis

Indexed keywords

EID: 84992037322     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5774-0_7     Document Type: Chapter

References (72)

1. Block JA, Sequeira W. Raynaud's phenomenon. Lancet. 2001;357(9273):2042-8.
2. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a twoyear, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999;42(6):1194-203.
3. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351-8.
4. Denton C, Merkel P, Furst D, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007;56(1):323-33.
5. Postlethwaite A, Wong W, Clements P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum. 2008;58(6):1810-22.
6. Khanna D, Clements P, Furst D, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement:a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(4):1102-11.
7. Rhew E, Barr W. Scleroderma renal crisis: new insights and developments. Curr Rheumatol Rep. 2004;6(2):129-36.
8. Mathai S, Hassoun P. Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr Opin Rheumatol. 2009;21(6):642-8.
9. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-5.
10. Medsger T. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am. 2003;29(2):255-73. vi.
11. Walker UA, Tyndall A, Czirjk L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66(6):754-63.
12. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine. 2002;81(2):139-53.
13. Reveille J, Solomon D. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49(3):399-412.
14. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum. 1980;23(6):617-25.
15. Wigley FM. When is scleroderma really scleroderma? J Rheumatol. 2001;28(7):1471-3.
16. Masi AT. Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol. 1988;15(6):894-8.
17. Scussel-Lonzetti L, Joyal F, Raynauld J-P, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine. 2002;81(2):154-67.
18. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986;13(5):911-6.
19. Poormoghim H, Lucas M, Fertig N, Medsger TA. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000;43(2):444-51.
20. Williams HJ, Alarcon GS, Joks R, et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol. 1999;26(4):816-25.
21. Mosca M, Tavoni A, Neri R, Bencivelli W, Bombardieri S. Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year. Lupus. 1998;7(2):95-100.
22. Bodolay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003;21(3):313-20.
23. Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G. Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol. 1998;17(3):195-201.
24. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148-59.
25. Venables PJW. Mixed connective tissue disease. Lupus. 2006;15(3):132-7.
26. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology. 2003;42(4):534-40.
27. Meyer O, Fertig N, Lucas M, Somogyi N, Medsger T. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007;34(1):104-9.
28. van den Hoogen FH, Spronk PE, Boerbooms AM, et al. Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies. Br J Rheumatol. 1994;33(12):1117-20.
29. Masi et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581-90.
30. Nadashkevich O, Davis P, Fritzler MJ. Revising the classification criteria for systemic sclerosis. Arthritis Rheum. 2006;55(6):992-3.
31. Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol. 2011;40(2):78-83.
32. Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol. 2004;22(3 Suppl 33):S5-13.
33. Hudson M, Taillefer S, Steele R, et al. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol. 2007;25(5):754-7.
34. Lonzetti LS, Joyal F, Raynauld JP, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum. 2001;44(3):735-6.
35. Steen V. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35-42.
36. Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988;31(2):196-203.
37. Arbuckle M, McClain M, Rubertone M, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-33.
38. Yamasaki Y, Honkanen-Scott M, Hernandez L, et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum. 2006;54(9):3051-6.
39. Parker JC, Burlingame RW, Webb TT, Bunn CC. Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology. 2008;47(7):976-9.
40. Villalta D, Morozzi G, Tampoia M, et al. Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis. Clin Chim Acta. 2010;411(9-10):710-3.
41. Hanke K, Brckner C, Dhnrich C, et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther. 2009;11(1):R22.
42. Mitri G, Lucas M, Fertig N, Steen V, Medsger T. A comparison between anti-Th/To-and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum. 2003;48(1):203-9.
43. Arnett FC, Reveille JD, Goldstein R, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum. 1996;39(7):1151-60.
44. Okano Y, Medsger TA. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum. 1990;33(12):1822-8.
45. Kasturi KN, Hatakeyama A, Spiera H, Bona CA. Antifibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes. J Exp Med. 1995;181(3):1027-36.
46. Satoh M, Ajmani AK, Ogasawara T, et al. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest. 1994;94(5):1981-9.
47. Kuwana M, Okano Y, Pandey J, Silver R, Fertig N, Medsger T. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum. 2005;52(8):2425-32.
48. Satoh T, Ishikawa O, Ihn H, et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology. 2009;48(12):1570-4.
49. Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy. Arthritis Rheum. 1973;16(5):619-28.
50. Maricq HR, LeRoy EC, D'Angelo WA, et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum. 1980;23(2):183-9.
51. Maricq HR, Weinberger AB, LeRoy EC. Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud's phenomenon. J Rheumatol. 1982;9(2):289-91.
52. Nagy Z, Czirjk L. Nailfold digital capillaroscopy in 447 patients with connective tissue disease and Raynaud's disease. J Eur Acad Dermatol Venereol. 2004;18(1):62-8.
53. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol. 2000;27(1):155-60.
54. Cutolo M, Pizzorni C, Tuccio M, et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology. 2004;43(6):719-26.
55. Smith V, Pizzorni C, De Keyser F, et al. Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann Rheum Dis. 2010;69(6):1092-6.
56. Anders HJ, Sigl T, Schattenkirchner M. Differentiation between primary and secondary Raynaud's phenomenon: a prospective study comparing nailfold capillaroscopy using an ophthalmoscope or stereomicroscope. Ann Rheum Dis. 2001;60(4):407-9.
57. Baron M, Bell M, Bookman A, et al. Office capillaroscopy in systemic sclerosis. Clin Rheumatol. 2007;26(8):1268-74.
58. Bauersachs RM, Lssner F. The poor man's capillary microscope. A novel technique for the assessment of capillary morphology. Ann Rheum Dis. 1997;56(7):435-7.
59. Muroi E, Hara T, Yanaba K, et al. A portable dermatoscope for easy, rapid examination of periungual nailfold capillary changes in patients with systemic sclerosis. Rheumatol Int. 2010.
60. Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter H-P, Kundi M. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum. 2006;54(6):1974-81.
61. Cutolo M, Pizzorni C, Sulli A. Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al. Arthritis Rheum. 2007;56(6):2102-3.
62. Koenig M, Joyal F, Fritzler M, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58(12):3902-12.
63. Johnson S, Feldman B, Hawker G. Classification criteria for systemic sclerosis subsets. J Rheumatol. 2007;34(9):1855-63.
64. Walker J, Pope J, Baron M, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol. 2007;26(9):1401-9.
65. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28(7):1573-6.
66. Ziswiler H-R, Urech R, Balmer J, Ostensen M, Mierau R, Villiger P. Clinical diagnosis compared to classification criteria in a cohort of 54 patients with systemic sclerosis and associated disorders. Swiss Med Wkly. 2007;137(41-42):586-90.
67. Nadashkevich O, Davis P, Fritzler M. A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit. 2004;10(11):CR615-21.
68. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22(7):1281-5.
69. Hudson M, Fritzler M, Baron M. Systemic sclerosis: establishing diagnostic criteria. Medicine. 2010;89(3):159-65.
70. Matucci-Cerinic M, Allanore Y, Czirjk L, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis. 2009;68(9):1377-80.
71. Avouac J, Fransen J, Walker U, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476-81.
72. Wollheim F. Classification of systemic sclerosis: visions and reality. Rheumatology. 2005;44(10):1212-6.